Cutaneous T cell lymphoma PDX drug screening platform identifies cooperation between inhibitions of PI3K α/δ and HDAC

Cutaneous T-cell lymphoma (CTCL) is a form of non-Hodgkin lymphoma that manifests initially in the skin and disseminates systemically as disease progresses. Mycosis fungoides and S ézary syndrome (MF/SS) are the most common subtypes of CTCL. Advanced MF/SS are life-threatening with few treatment options. We searched for new agents by high-throughput screening of selected targeted compounds and identified high value targets including phosphatidylinositol 3-kinase (PI3K) and cy clin-dependent kinases.

Source: Journal of Investigative Dermatology - June 26, 2020 Category: Dermatology Authors: Chi-Heng Wu, Chen-Yen Yang, Linlin Wang, Hua-Xin Gao, Taha Rakhshandehroo, Shervin Afghani, Laura Pincus, Ronald Balassanian, James Rubenstein, Ryan Gill, Sourav Bandyopadhyay, Frank McCormick, Mark Moasser, Weiyun Z. Ai Tags: Original Article Source Type: research